On July 16, 2026, Cencora Inc (COR) shares rose 3.9% to a current price of $307.99. This price perfo

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Gr

Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securit

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to relea

B of A Securities analyst Michael Funk maintains Cencora (NYSE:COR) with a Neutral and raises the

COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansio

COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underwa

Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings gr

The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announ

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia

Barclays analyst Glen Santangelo maintains Cencora (NYSE:COR) with a Overweight and lowers the pr

The shares of both stocks are down so far this year. Stevanato is benefiting from the need for GLP-1

COR bets on MSOs, specialty logistics and AI tools to deepen ties beyond distribution???even as GLP-

Cencora (COR) reported earnings 30 days ago. What's next for the stock?

The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While t

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

The battle between Amazon.com and Walmart has produced a new leader for the Fortune 500 list for 202

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

CAH and COR are betting big on specialty pharma, but Cardinal Health???s stronger growth, raised out

Cencora, Inc. (NYSE:COR) today announced Eva C. Boratto has been appointed Executive Vice President

Cencora, Inc. (NYSE:COR) today updated its fiscal year 2026 financial guidance as a result of recent

Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Overweight and lowers the

Citigroup analyst Daniel Grosslight maintains Cencora (NYSE:COR) with a Buy and lowers the price

Evercore ISI Group analyst John Belton maintains Cencora (NYSE:COR) with a Outperform and lowers

Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and lowers the price t

Cencora stock falls after Q2 earnings miss and lower sales guidance, despite raising EPS outlook and

U.S. stocks hit records as Trump's Iran memo sinks oil 6%, AMD soars 17% on data-center beat.

Cencora (NYSE:COR) raises FY2026 Adj EPS guidance from $17.45-$17.60 to $17.65-$17.90 vs $17.60 anal

Cencora (NYSE:COR) reported quarterly earnings of $4.75 per share which missed the analyst consensus

Evercore ISI Group analyst John Belton maintains Cencora (NYSE:COR) with a Outperform and lowers

Cencora, Inc. (NYSE:COR) today announced the signing of a definitive agreement to acquire EyeSouth P

U.S. stocks rebound as investors look past rising oil prices and focus on the Fed's rate decisio

COR stock dips as Cencora announces CFO James Cleary's retirement. Read the full details on the

Cencora (NYSE:COR) and Covetrus, a global animal health technology and services company, today annou

Barclays analyst Glen Santangelo maintains Cencora (NYSE:COR) with a Overweight and raises the pr

JP Morgan analyst Lisa Gill maintains Cencora (NYSE:COR) with a Overweight and raises the price t

Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Overweight and raises the

Evercore ISI Group analyst John Belton maintains Cencora (NYSE:COR) with a Outperform and lowers

Cencora reported higher Q1 earnings but missed revenue estimates, driven by U.S. and European drug s